Skip to content

Basket

You currently have no items in your basket.

Total (excl. vat) £0.00
View basket & checkout
Antibodies

SUMO1 Recombinant Monoclonal Antibody

Product Sizes
50 ul
£235.00
CSB-RA022948A0HU-50UL
100 ul
£392.00
CSB-RA022948A0HU-100UL
About this Product
SKU:
CSB-RA022948A0HU
Additional Names:
Small ubiquitin-related modifier 1, SUMO-1, GAP-modifying protein 1, GMP1, SMT3 homolog 3, Sentrin, Ubiquitin-homology domain protein PIC1, Ubiquitin-like protein SMT3C, Smt3C, Ubiquitin-like protein UBL1, SUMO1, SMT3C, SMT3H3, UBL1, OK/SW-cl.43
Application:
ELISA, Flow Cytometry, Immunohistochemistry, Immunoprecipitation
Buffer:
phosphate buffered saline
translate.label.attr.clone:
5G3
Clonality:
Recombinant Monoclonal
Extra Details:
Ubiquitin-like protein that can be covalently attached to proteins as a monomer or a lysine-linked polymer. Covalent attachment via an isopeptide bond to its substrates requires prior activation by the E1 complex SAE1-SAE2 and linkage to the E2 enzyme UBE2I, and can be promoted by E3 ligases such as PIAS1-4, RANBP2 or CBX4. This post-translational modification on lysine residues of proteins plays a crucial role in a number of cellular processes such as nuclear transport, DNA replication and repair, mitosis and signal transduction. Involved for instance in targeting RANGAP1 to the nuclear pore complex protein RANBP2. Covalently attached to the voltage-gated potassium channel KCNB1; this modulates the gating characteristics of KCNB1 (PubMed:19223394). Polymeric SUMO1 chains are also susceptible to polyubiquitination which functions as a signal for proteasomal degradation of modified proteins. May also regulate a network of genes involved in palate development. Covalently attached to ZFHX3 (PubMed:24651376).
Immunogen:
A synthesized peptide derived from human SUMO1
Isotype:
IgG
Physical State:
Liquid
Purification:
Affinity Purified
Reactivities:
Human
Shipping Conditions:
Blue Ice
Storage Conditions:
-20[o]C/-70[o]C Avoid freeze/thaw cycles.
Supplier:
Cusabio
Type:
Antibody: Recombinant Antibodies
Overlay histogram showing Hela cells stained with CSB-RA022948A0HU (red line) at 1:50. The cells were fixed with 70% Ethylalcohol (18h) and then permeabilized with 0.3% Triton X-100 for 2 min. The cells were then incubated in 1x PBS /10% normal goat serum to block non-specific protein-protein interactions followed by primary antibody for 1 h at 4°C. The secondary antibody used was FITC goat anti-rabbit IgG (H+L) at 1/200 dilution for 1 h at 4°C. Control antibody (green line) was used under the same conditions. Acquisition of >10,000 events was performed.
IHC image of CSB-RA022948A0HU diluted at 1:92.5 and staining in paraffin-embedded human adrenal gland tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.
IHC image of CSB-RA022948A0HU diluted at 1:92.5 and staining in paraffin-embedded human liver cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.
Immunoprecipitating SUMO1 in 293T whole cell lysate Lane 1: Rabbit control IgG instead of CSB-RA022948A0HU in 293T whole cell lysate. For western blotting, a HRP-conjugated Protein G antibody was used as the secondary antibody (1/2000) Lane 2: CSB-RA022948A0HU (3ug) + 293T whole cell lysate (500ug) Lane 3: 293T whole cell lysate (20ug)